A Reported Stopgap for Restricted Peptides: What Is Confirmed, and What Is Not

On October 7, 2026 the Washington Post reported that the Trump administration is drafting plans to allow the temporary sale of certain previously restricted peptides while federal health officials write new regulations for them. The plan has not been announced, and the report, which cites two people familiar with the matter speaking anonymously, does not say which peptides would be covered or when any change would begin.

Update, October 22: on October 14 the FDA sent a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House regulatory office for review. Its text is not public. Our follow-up covers what the filing confirms.

As relayed by Reuters and by several policy outlets, the Post's account is that the plan would let some compounding pharmacies dispense certain peptides marketed as treatments and wellness products even though their claimed benefits have not been fully tested for safety. The Post also noted that FDA scientists and some medical experts have raised concerns about widening access to certain peptides, a position the agency's own reviewers put on the record before the July advisory meeting. That is the whole of what has been reported. Everything else in this piece is either background that is on the public record or a description of the mechanisms that already exist.

What is not known

Which peptides. The report did not identify them. The obvious candidates are the six an FDA advisory committee recommended in July, but nothing published so far confirms the list.

The mechanism. A temporary path could take more than one form, and the report did not specify one.

The timing, and whether it happens at all. A drafted plan described by anonymous sources can change or be dropped. As of October 22, a notice is under White House review with no deadline and no published text, and neither the FDA nor the Department of Health and Human Services has announced the policy itself.

How a stopgap could work under existing rules

There is already a tool built for this kind of interim period. Under the FDA's interim policy for compounding with bulk substances, while a nominated substance is still being evaluated for the 503A bulks list, the agency does not intend to take action against a state-licensed pharmacy compounding with it, provided the substance sits in what the policy calls Category 1 and other conditions are met. That is enforcement discretion: a statement about where the agency will spend its attention, not a change in the law.

The Alliance for Pharmacy Compounding, the trade group for compounding pharmacies, says it has met with the FDA twice to ask for exactly this: interim enforcement discretion so state-licensed pharmacies could prepare these peptides for patients with prescriptions, with conditions attached, including enhanced patient disclosures, serious adverse event reporting and data collection on peptide use. Whether the reported plan takes that shape is not yet known.

How we got here

2023. The FDA placed a group of peptides, BPC-157 among them, in Category 2 of its interim compounding policy, reserved for substances that may present significant safety risks.

February 27, 2026. Health Secretary Robert F. Kennedy Jr. said about 14 of the 19 restricted peptides would be made more accessible through compounding.

April 15, 2026. The FDA gave notice that it would remove 12 peptides from Category 2 because their nominators had withdrawn the nominations. It did not move them into Category 1, which left them outside the interim enforcement-discretion policy. The one exception is GHK-Cu, which the FDA's list as updated on May 14 shows back in Category 1 for non-injectable routes only. Law firm Orrick described the result as a regulatory gray area until the advisory committee met and the FDA took final action.

July 23 and 24, 2026. The Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. It voted against emideltide. The FDA's own briefing documents had proposed against including them, citing among other things the absence of human data. The BPC-157 vote was 8 to 6 with one abstention. We covered that meeting at the time.

October 7, 2026. The Post report. We could find no proposed or final rule adding any of the six to the 503A bulks list as of this writing, and the committee is scheduled to take up further peptides before the end of February 2027.

October 14, 2026. The White House regulatory office receives the FDA's interim access policy for review. The AP reported on October 15, citing two unnamed sources, that it would rely on enforcement discretion and would cover BPC-157.

What a stopgap would not do

It would not approve anything. Compounding under enforcement discretion is a pharmacy preparing a medication for an individual patient with a prescription. It is not an FDA approval, it does not establish that a compound works or is safe, and it is not the same as a final listing on the 503A bulks list. Our explainer on whether peptides are FDA-approved sets out the difference.

It would not touch the research market. A compounding pathway concerns pharmacies and prescriptions. Material sold online as research chemicals would sit exactly where it sits now, and the FDA's August warning letters to online sellers show the agency still treats human-use marketing in that channel as an enforcement matter.

It would not settle the safety argument. After the July vote, the patient-safety organizations ECRI and the Institute for Safe Medication Practices said the evidence on safety and efficacy remained inadequate, and that any access should come with demonstrated safety, verified manufacturing quality and adverse-event monitoring. The trade group asking for interim access has proposed some of the same safeguards. The difference is whether they come before access or alongside it.

What to watch

A formal announcement from the FDA or HHS naming specific substances. Any change to the FDA's published category lists, which is where an interim policy would show up in writing. And a proposed rule for the 503A bulks list, which is the step that would make any of this permanent.

We will cover the primary document when there is one.

Sources:

Nothing here is legal or medical advice. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication